Brought to you by 
JHP Pharmaceuticals buys NitroMed's BiDil for $26.3mm; ends
30 Jan 2023
Executive Summary
JHP Pharmaceuticals has bought all of NitroMed's BiDil (isosorbide dinitrate/hydralazine) assets for $24.5mm in cash plus $1.8mm for inventory and will assume certain liabilities.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
JHP Pharmaceuticals buys NitroMed's BiDil for $26.3mm; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice